Kornimate/medical-research-clean huggingface dataset:
fluoroethyltyrosine for evaluation of intracranial neoplasms

Conditions: Intracranial Neoplasm; Low Grade Glioma; Recurrent Glioblastoma; Recurrent World Health Organization (WHO) Grade II Glioma; Recurrent WHO Grade III Glioma

Summary: this phase ii trial studies how well f-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. fet accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. imaging agents such as fet can help oncologist to see the tumor better during a positron emission tomography (pet) scan.

primary objectives: i. to determine if f-18 fluoroethyltyrosine (fet) pet can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with recurrent metastatic disease and high-grade gliomas. ii. to determine if fet pet can accurately differentiate between low-grade and high-grade gliomas in population 2. secondary objectives: i. to determine if fet pet can differentiate between benign treatment-related changes and recurrence in comparison to pathology or imaging follow-up in population 1. ii. to determine if fet pet can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with recurrent low-grade gliomas. outline: participants receive f-18 fluoroethyltyrosine intravenously (iv) over approximately 1 minute and undergo pet over 40 minutes. after completion of study treatment, participants are followed up periodically.

Eligibility criteria:
inclusion criteria: * age \> 3 years. * presence or suspicion of intracranial neoplasm in two populations. * population 1: patients after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on magnetic resonance imaging (mri). three sub-populations will be considered: * recurrent metastatic lesions. * recurrent high-grade gliomas (grades 3 and 4). * recurrent low-grade gliomas (grades 1 and 2). * population 2: patients prior to primary treatment with planned biopsy or surgical resection. exclusion criteria: * patient with known incompatibility to pet or computed tomography (ct)/mri scans. * patient unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation. * sedation or anesthesia can be used for patients who cannot tolerate the exam.
comparison of high and low pulse energy dusting protocols using holmium: yag-laser in flexible ureteroscopy for renal stones treatment

Conditions: Renal Stone

Summary: rcompare high-energy versus low-energy laser settings in renal stone lithotripsy using low power machines) holmium yag 30 watts, examining their respective advantages, limitations, and overall efficacy.

the prevalence of urinary stone disease treatment has shown a continuous updating within the armamentarium of urinary stone management, the laser has emerged as a cornerstone for lithotripsy in endourological procedures. the laser technology has witnessed a progressive evolution, transitioning from the established holmium: yttrium-aluminum-garnet (ho:yag) laser with pulse modulation to the advent of thulium fiber laser (tfl) and, more recently, the innovative pulsed thulium:yag (p-tm:yag) laser laser lithotripsy is prefered for its minimally invasive approach and high success rates in fragmenting stones, yet the ongoing debate continues regarding the optimal laser power settings for this procedure. contemporary approaches in laser lithotripsy focus on two primary strategies: fragmenting stones into smaller retrievable parts or breaking them into minute fragments, commonly referred to as 'dust,' facilitating the natural passage of smaller particles the choice between high power and low power settings in laser lithotripsy significantly influences treatment outcomes, including stone fragmentation efficiency, procedural time, and potential tissue damage. high-energy power laser settings offer rapid stone ablation capabilities, enabling quick fragmentation but potentially raising concerns about thermal injury to surrounding tissues. in contrast, low-energy power settings, while reducing the risk of tissue damage, might prolong the procedure and necessitate additional maneuvers for complete stone clearance this study aims to compare high-energy versus low-energy laser settings in renal stone lithotripsy using low power machines) holmium yag 30 watts, examining their respective advantages, limitations, and overall efficacy. by scrutinizing existing literature and recent studies, this study intends to provide a 56 comprehensive understanding of the clinical implications of choosing optimal laser settings in urolithiasis comprehensive understanding of the clinical implications of choosing optimal laser settings in urolithiasis.

Eligibility criteria:
inclusion criteria: * adult patients * hard renal stones * less than 2 cm * hounsfield unit of ≥ 1000 exclusion criteria: * patients less than 18 years * ureteral stones * stones with hounsfield units less than 1000 * stones in calyceal diverticulum * patients with coagulopathy were also excluded from the study.
sing out loud: a choral singing program for persons living with dementia

Conditions: Dementia; Nursing Homes Residents

Summary: we intend to investigate whether a singing programme for nursing home residents living with dementia can reduce the mental and physiological effects of dementia. the main questions it aims to answer are: 1. does participating in the sing out loud (sol) singing intervention lead to an improvement in the physiological well-being (increase in oxytocin and reduction in cortisol levels) of persons living with dementia (pwds) in nursing homes? 2. will participation in the sol singing intervention result in an improvement in pwds' overall mood, temperament, and mental health (indicated by symptoms such as apathy, aggression, and depression). researchers will compare the singing group to the control group to see if they exhibit reduced levels of apathy, aggression, and depression, and whether their levels of oxytocin and cortisol (collected via salivary biomarkers) have increased and decreased, respectively. researchers will compare the sol singing intervention with a waitlist control group to see if the sol singing intervention increases the feelings of social connection, reduces stress, or improves the symptoms of dementia in nursing home residents. participants will be randomly assigned to a singing intervention or waitlist control group. the intervention involves an 8-week long singing programme with one practice session a week, culminating in an additional full dress rehearsal and private showcase performance for their family members at a concert venue.


Eligibility criteria:
inclusion criteria for patients: * aged 59 to 90 years old * diagnosed with dementia * living in the nursing home * interested in participating in the sol programme * able to provide saliva samples exclusion criteria for patients: * unable to provide saliva samples inclusion criteria for psychologists: * aged 21 to 65 years old * is the psychologist of a patient who is participating in the sol programme * is able to speak english exclusion criteria for the psychologists: * unable to complete the npi-q questionnaire for their patient who is participating in the sol programme * decline audio recording during the focus group discussion

Keywords: dementia nursing home residents singing biomarkers npi-q
modified video-assisted thoracoscopic surgery (vats) lobectomy for early-stage non-small cell lung cancer (nsclc)

Conditions: Lung Cancer

Summary: the purpose of this study is to modify the surgical technique of vats (video-assisted thoracoscopic surgery) lobectomy for early-stage non-small cell lung cancer.

vats (video-assisted thoracoscopic surgery) lobectomy is a relatively new minimally invasive surgical treatment for early-stage non-small cell lung cancer (nsclc), associated with low morbidity and mortality and effective oncologic results over the standard thoracotomy. however, this surgical procedure has not spread widely in china for several reasons. first , vats surgery cost more than thoracotomy for thoracoscopic staples; second, the procedure of vats lobectomy may be more difficult in china as the lack of vats surgical equipments adjusted for smaller thoracic cavity of chinese, and more common adhesive and calcified lymph nodes due to infection and tuberculosis; third, the surgical levels of vats lobectomy are far from equal in china, and the continuing medical education training programs of thoracoscopic surgery seem to be less efficient without major criterion. the purpose of this study is to modify the surgical technique of vats (video-assisted thoracoscopic surgery) lobectomy for early-stage non-small cell lung cancer, to examine the feasibility of vats lobectomy performed by less staples, and to evaluate the feasibility of vats lobectomy performed by modified surgical equipments designed according to the experience of chinese lobectomy surgery, and to generate a chinese standard operative procedure of vats lobectomy for technique learning and spread. the investigators will intend to recruit 250 patients each group, for 4 groups. group a(open group) will undergo radical lobectomy via thoracotomy approach. group b(standard vats group) will undergo lobectomy via standard vats approach introduced. group c(less staples group) will undergo lobectomy via vats approach with staples limitation. group d(modified equipments group) will undergo lobectomy via vats approach using vats surgical equipments designed according to the experience of chinese lobectomy surgery. the investigators will compare two groups of patients as followed: a vs. b, b vs. c, b vs. d.

Eligibility criteria:
inclusion criteria: 1. clinically diagnosed with stage i to stage ii peripheral non-small cell lung cancer suitable for lobectomy. 2. signed informed consent from patient or legal representative, and allowed adequate follow-up. 3. operators must have experience of vats lobectomy for more than 50 cases. exclusion criteria: 1. pregnant or breastfeeding women. 2. severe complications or infections. 3. no prior chemotherapy or radiotherapy for this malignancy. 4. medical history of mediastinal or hilar lymphadenopathy. 5. current participation in another study involving an investigational device or drug.

Keywords: video-assisted thoracic surgery lung cancer lobectomy
choline pet/ct and mri for targeted prostate biopsy

Conditions: Prostate Cancer

Summary: this research study will access the using of a radiotracer, 18f-choline pet/ct and mri for prostate cancer in patients undergoing diagnostic prostate biopsy. patients receive mri guided prostate biopsies and metabolomic profiling of prostate biopsy tissues.

this is an explorative diagnostic basic research study to assess the value of 18f-choline pet/ct and multi-sequence mri for prostate cancer in patients undergoing diagnostic prostate biopsy. patients will receive image-guided (targeted) prostate biopsies and metabolomic profiling of prostate biopsy tissues to evaluate underlying metabolic changes in comparison with pathological gleason grading.

Eligibility criteria:
inclusion criteria: * males 40 years of age or older scheduled for prostate biopsy (for known or suspected prostate cancer) followed by planned prostatectomy (population group a) * males 40 years of age or older with known (biopsy-confirmed) primary adenocarcinoma of the prostate undergoing active surveillance scheduled for prostate biopsy (population group b) exclusion criteria: * androgen ablation (hormone treatment) within the last 3 months * prostate biopsy within 6 weeks prior to pet or mri imaging * active inflammatory bowel disease within the last 6 months * acute prostatitis within the last 6 months * a non-urologic bacterial infection requiring active treatment with antibiotics * active other malignancy (except basal cell or squamous cell skin cancer) within the last 2 years * previous radiation treatment of the pelvis * symptomatic distal rectal stenosis * known hypersensitivity to glucagon * pheochromocytoma, insulinoma or galactosemia * insulin-dependent diabetes

Keywords: prostate cancer biopsy 18f-choline pet mri
a study in participants with asthma initiating treatment with omalizumab (xolair)

Conditions: Asthma

Summary: this multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.


Eligibility criteria:
inclusion criteria: * participants identified by the investigator as a candidate for treatment for asthma with omalizumab * confirmation of access to omalizumab through insurance or other source of funding exclusion criteria: * enrollment in any other concurrent clinical trial or observational study * participants for whom omalizumab treatment is contraindicated * participants who had a prior allergic reaction to omalizumab or its excipients * participants treated with omalizumab within the previous year * participants who received an experimental drug as part of another study within 3 months of enrollment
arthroscopic resection arthroplasty of carpometacarpal and/or pantrapezial osteoarthritis

Conditions: Thumb Osteoarthritis

Summary: compare outcomes of ara for isolated cmc oa versus to simultaneous ara of cmc plus stt

the purposes of this study were to report 1) long-term outcomes on a large series of patients that underwent arthroscopic resection arthroplasty (ara) for thumb basal joint arthritis (bja) and 2) to compare outcomes of ara for isolated carpometacarpal osteoarthritis versus those undergoing simultaneous ara of cmc plus the scaphotrapeziotrapezoid joint for pantrapezial disease. please note, all patients treated by dr. cobb for cmc and/or stt oa received the same treatment regardless of whether or not they chose to participate in the study. patients who chose to enroll in the study received the same treatment as those who did not only their data was analyzed. data collection is the same for those who do not participate, only their data is not analyzed.

Eligibility criteria:
inclusion criteria: * primary cases of ara for thumb bja with isolated cmc ara or simultaneous ara of the cmc and stt joints. exclusion criteria: * exclusions included 19 cases that received interposition materials that since have been shown to produce unfavorable postoperative inflammatory responses, (orthadapt bioimplant, pegasus biologics, irvine, ca and artimplant artelon cmc-i spacer, small bone innovations, llc, new york, ny), 6 cases that had prior cmc surgery, and 27 cases that underwent concomitant surgeries that would potentially effect outcome.
development of an anxiety sensitivity-based intervention for substance use and anxiety comorbidity

Conditions: Other (or Unknown) Substance Use Disorders

Summary: the aim of the current study is to develop and pilot test an anxiety sensitivity-based intervention for co-occurring substance use disorders (suds) and anxiety. research questions include determining whether a broadly-applicable as-based intervention can significantly decrease both substance misuse and anxiety. secondary aims include examining the impact of this intervention on general functioning and depressive/anxious symptoms. in phase i, an initial pilot was conducted to examine the feasibility, safety, and patient satisfaction with the protocol, and to estimate potential efficacy of the protocol. in phase ii, participants will be randomized to the intervention or a control condition.

the aim of the current study is to develop and pilot test an anxiety-sensitivity based intervention for co-occurring suds and anxiety. in the proposed study, the investigators will develop, refine, and pilot-test an innovative cognitive-behavioral therapy (cbt) for patients who suffer from substance use disorders as well as anxiety. the goal of the research group in the proposed study is to design a protocol that can be testable on a larger sample within an externally-funded, randomized controlled trial. the investigators plan to submit a proposal for this larger grant to the national institute on drug abuse, as outlined in our external funding statement. research questions include determining whether a broadly-applicable anxiety sensitivity based intervention can significantly decrease both substance misuse and anxiety. secondary aims include examining the impact of this intervention on general functioning and depressive/anxious symptoms. in this translational research project, strategies that have been demonstrated to impact the psychological mechanisms thought to underlie both illnesses will be tested in a "real world" clinical setting.

Eligibility criteria:
inclusion criteria: * score higher than 25 (established clinical cutoff) on the anxiety sensitivity index (asi; peterson \& plehn, 1999) * meet the dsm diagnostic criteria for current substance abuse or psychological dependence exclusion criteria: * active psychosis, suicidality, mania, or current physiological withdrawal symptoms that necessitate medical detoxification; no substance use in the past 3 months

Keywords: substance use disorders anxiety anxiety sensitivity brief intervention treatment
effect of nasal continuous positive airway pressure (cpap) on oral feeding in human neonates

Conditions: Oral Feeding in Human Neonates During Nasal CPAP

Summary: current knowledge suggests that, to be successful, oral feeding in preterm babies should be initiated as soon as possible, often at an age where immature respiration still requires ventilatory support in the form of continuous positive airway pressure (cpap). while some neonatologist teams claim great success with initiation of oral feeding in immature babies with cpap, others strictly wait for cpap to be no longer necessary before any attempt at oral feeding. such controversy is fuelled by ignorance of the effects of cpap on nutritive sucking and swallowing, including their coordination with breathing, and the fear to induce deleterious problems such as pulmonary aspiration of milk and/or respiratory failure. ensuing delay in becoming proficient with oral feeding unduly prolongs hospital stays of preterm babies. the aim of this study is to evaluate the effects of nasal cpap on oral feeding in human neonates. more specifically, cpap effects on nutritive sucking and swallowing, including on breathing-swallowing coordination, will be carefully assessed. the investigators hypothesize that nasal cpap will lead to no or minimal alterations of breathing-nutritive swallowing coordination and will not induce deleterious cardiorespiratory events. accordingly, each neonate will be evaluated during 2 bottle feedings spaced of 24 h, one with nasal cpap 5 cm h2o and the other without any cpap. sucking and swallowing activity, respiration, heart rate and oxygenation will be continuously recorded before, during and after bottle-feeding. by filling a gap in knowledge, results from the study will hopefully help neonatologists afraid of doing more harm than good when initiating bottle-feeding in preterm babies under cpap to join the many teams for whom it is no more a problem.


Eligibility criteria:
inclusion criteria: * gestational age 24 weeks or more * hospitalized in the neonatology unit or the maternity unit of chus fleurimont * feeds by complete oral feeding since 24 hours or more exclusion criteria: * upper airways anomaly * brain injury : periventricular leukomalacia or intracranial hemorrhage \> grade iii (papile classification) * neuromuscular disease * life-threatening congenital disease * any symptomatic intercurrent acute disease (ex.: infection)

Keywords: neonate oral feeding nasal cpap sucking swallowing breathing
nano-pulse stimulation (nps) in seborrheic keratosis optimization study

Conditions: Lesion Skin; Seborrheic Keratosis; Skin Lesion; Benign Skin Tumor

Summary: primary study objective is to evaluate the optimization of nano-pulse stimulation (nps) energy settings for lesion clearance of seborrheic keratosis (sks) from off-facial areas of healthy adults.

* evaluate lesion clearance rate of sks in off-face locations post-treatment versus baseline using multiple sized treatment tips with microneedles. * evaluate the clearance of the treated sks using multiple energy settings at various time points initial procedure, compared baseline. * evaluate skin effects and adverse event rate.

Eligibility criteria:
inclusion criteria: * male or female between 21 and 75 years of age * voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained * understanding of the clinical investigation, agree to cooperate with the investigational procedures and willing to return for all the required follow-up visits * understands that sks are to be treated in a single treatment session and is aware that they may receive a second treatment * must be able to visit clinic site at 7-, 30-, 60-, and 90-days post-primary treatment of sk lesion and at retreatment * clinical diagnosis of stable, clinically typical seborrheic keratosis * minimum of two sk lesions * sks must be no greater than 2mm in height and not exceed 10mm x 10mm at their largest point * undergo all study procedures including consent for global photographs of the sk study sites * agrees to refrain from using all other sk lesion removal products or treatments (topical medication including over-the-counter medications) during the study period exclusion criteria: * implantable electronic devices (i.e., automatic defibrillator) * active infection or history of infection in designated test area within 90 days prior to first treatment * not willing or able to sign the informed consent * known to be immune-compromised * known to be keloid producer * taking blood thinning medications * insulin dependent, type i diabetics * allergies to lidocaine or lidocaine-like products * employed by the sponsor, clinic site, or entity associated with the conduct of the study * family member of someone employed by the sponsor, clinic site, or entity associated with the conduct of the study * have any condition or situation which, in the investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study * prior inability to complete required study visits during treatment period. * use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study